Biomedical papers, 2016 (vol. 160), issue 1

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016, 160(1):84-93 | 10.5507/bp.2015.032

Relationship of differences in immunoglobulin heavy/light chain pairs (HevyliteTM), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma

Vlastimil Scudlaa,c, Pavel Lochmanb, Tomas Pikac, Jiri Minarikc, Jana Zapletalovad, Jaroslav Bacovskyc
a Department of Internal Medicine III - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
b Department of Clinical Biochemistry, University Hospital Olomouc, Czech Republic
c Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
d Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic

Background and Aims: Advances in the diagnosis and treatment of multiple myeloma (MM), place increasing demands on accurate stratification of patients as the starting point for optimal individualized therapy. The present study focused on assessing the association between HLC levels and the HLC-r to parameters of MM activity, prognosis and tumor mass volume.The objective was to assess the correlation of immunoglobulin (Ig), heavy/light chain (HLC) pairs (IgG-κ and-λ, IgA-κ and -λ HLC) and the ratio of monoclonal involved-HLC (i-HLC) to polyclonal uninvolved (u-HLC) Ig concentrations assessed by the HevyliteTM method with the free light chain κ/λ ratio (FLC-r), selected prognostic laboratory parameters i.e. Hb, platelets, albumin, β2-microglobulin (β2-M), Ca, lactate dehydrogenase (LDH), creatinine and the Durie-Salmon (D-S) and International Staging System (ISS), stages (1-3) for MM.

Methods: HevyliteTM assays were done on the sera of 132 MM patients at the time of diagnosis (IgG 94, IgA 38). HLC-r was calculated in the case of i-HLC-κ from the i-HLC-κ/u-HLC-λ ratio and for i-HLC-λ from the i-HLC-λ/u-HLC-κ ratio. D-S and ISS stages were evenly distributed.

Results: Md IgG-κ HLC-r was 64.8 (2.7-2222) and of IgG-λ HLC-r 49.6 (0.7-465.1), in the case of IgA-κ, Md HLC-r was 408.9 (3.4-3966) and for IgA-λ HLC-r the Md was 180.0 (0.1-3110). Normal levels of HLC pairs and HLC-r did not always rule out the diagnosis of MM. HLC-r correlated with FLC-r in IgG (r = 0.244, P = 0.018), but not in the IgA type. For IgG, HLC-r values were significantly different in patients with abnormal vs normal levels of Hb (P < 0.0001), albumin (P < 0.043), β2-M (P < 0.0001) and creatinine (P = 0.034) but not thrombocyte count, Ca or LDH. For the IgA isotype, we found a significant difference in HLC-r values only for thrombocyte count (P = 0.026) and β2-M (P = 0.016) but not for Hb, albumin, Ca, LDH or creatinine. For the IgG isotype there was a significant relationship of HLC-r index to stages 1-3 (P = 0.038) and substage A vs B (P = 0.048) according to D-S, and with high significance to stages 1-3 according to ISS (P = 0.005) and between stages 1 vs 3 (P = 0.001). For the IgA isotype, we found significant differences in HLC-r only between stages 1-3 (P = 0.025) according to D-S but not in the case of ISS. There were no significant correlations between i-HLC Ig levels and D-S or ISS stages in both IgG-κ and λ and IgA-κ and λ. Exceptions were significant differences for stages 1 vs 3 (P = 0.012) and 2 vs 3 (P = 0.017) for the IgG-λ isotype. There were no correlations of the HLC-r and u-HLC levels for either D-S or ISS stratifications in all HLC isotypes.

Conclusion: We found a significant positive contribution of HLC-r using the i-HLC/u-HLC ratio even in the case of i-HLC-λ i.e. i-HLC-λ/u-HLC-κ. Variable results for the relationship of important laboratory parameters and D-S and ISS stratifications (stage 1-3) to HLC-r values in IgG and IgA isotypes make separate interpretation of the HevyliteTM method results necessary in clinical practice.

Keywords: multiple myeloma, heavy/light chain measurements, heavy/light chain ratio, free light chain ratio, prognostic parameters, multiple myeloma stratification

Received: January 6, 2015; Accepted: June 19, 2015; Prepublished online: August 4, 2015; Published: March 30, 2016


References

  1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Langren O, Paiva B, Dispenzieri A, Weiss B, Leleu X, Zweengman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM, San Miguel JF. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48. Go to original source... Go to PubMed...
  2. Bradwell AR. Analysis of immunoglobulin heavy chain/light chain pairs (HevyliteTM ). In: Bradwell AR, editor. Serum free light chain analysis (plus Hevylite). Birmingham: 6th edit. The Binding Site Ltd; 2010. p. 301-320.
  3. Bradwell AR, Harding S, Fourrier N, Mathiot C, Attal M, Moreau P, Harousseau J-L, Avet-Loiseau H. Prognostic utility of intact immunoglobulin Ig´κ /Ig´λ ratios in multiple myeloma patients. Leukemia 2013;27:202-7. Go to original source... Go to PubMed...
  4. Ludwig H, Milosavljevic D, Zojer N, Faint JM, Bradwell AR, Hübl W, Harding SJ. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia 2013;2 7:213-19. Go to original source... Go to PubMed...
  5. Hajek R, Adam Z, Scudla V, Maisnar V, Bacovsky J, Spicka I, Krejci M, Kessler P, Minarik J, Sandecka V, Radocha J. Guidelines of Czech myeloma group (CMG) 2012- Diagnosis and treatment of multiple myeloma. Transf Hematol 2012;18:5-89.
  6. Vavrova J. Assessment of free light chains and HevyliteTM in monoclonal gammopathies. In: Maisnar V, Tichy M, editors. Monoclonal immunoglobulins - occurrence, significance and possibilities of their detection. Praha: 1st edit. Nucleus Hradec Kralove; 2012. p. 55-60.
  7. Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, Rajkumar SV, Dispenzieri A. Screening panels for detection of monoclonal gammopathies. Clin Chemistry 2009;55:1517-22. Go to original source... Go to PubMed...
  8. Keren DF. Heavy/light-chain analysis of monoclonal gammopathies. Clin Chemistry 2009;55:1606-8. Go to original source... Go to PubMed...
  9. Wolff F, Debaugnies F, Rozen L, Willems D, Brohet F, Brauner J, Stordeur P. Assessment of the diagnostic performance of IgA heavy and light chain pairs in patients with IgA monoclonal gammopathy. Clin Biochemistry 2013;46:79-84. Go to original source... Go to PubMed...
  10. Bradwell AR, Harding SJ, Fourrier NJ, Wallis GLF, Drayson MT, Carr-Smith HD, Mead GP. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin κ/λ ratios. Clin Chemistry 2009;55:1646-55. Go to original source... Go to PubMed...
  11. Scudla V, Pika T, Hermanova Z. Hevylite - the new analytic method in diagnostics and monitoring of monoclonal gammopathies. Klin Biochem Metab 2010;18:62-8.
  12. Koulieris E, Panayiotidis P, Harding SJ, Kafasi N, Maltezas D, Bartzis V, Tzenou T, Dimou M, Georghiou G, Mirbahai L, Bradwell AR, Kyrtsonis MCH. Ratio of involved/uninvolved immunoglobulin quantification by HevyliteTM assay: clinical and prognostic impact in multiple myeloma. Exp Haematol & Oncol 2012;1:9. Available from: http://www.enhoonline.org/content/1/1/9 Go to original source...
  13. Pika T, Hermanova Z, Lochman P, Zapletalova J, Minarik J, Bacovsky J, Scudla V. System HevyLiteTM and IgA monoclonal gammopathy - first experience. Klin Biochem Metab 2011;19:86-91.
  14. Kraj M. Immunoglobulin heavy chain/light chain pairs (HLC, HevyliteTM) assays for diagnosing and monitoring monoclonal gammopathies. Adv Clin Exp Med 2014;23:127-33. Go to original source... Go to PubMed...
  15. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20. Go to original source... Go to PubMed...
  16. Scudla V, Lochman P, Pika T, Zapletalova J, Minarik J, Bacovsky J. Analysis of the relationship of heavy/light chain pairs of immunoglobulin (HevyliteTM) to the results of gel electrophoresis and nephelometric examination of serum proteins at the time of multiple myeloma diagnosis. Cas lek Ces 2015; (in press).
  17. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9. Go to original source... Go to PubMed...
  18. Manier S, Dulery R, Duhamel A, Boyle E, Rossignol J, Faucompret JL, Onraed B, Hennache B, Pietrantuono A, Combat F, Poulain S, Ghobrial IM, Leblond V, Harding S, Leleu X. HevyliteTM, a new marker of tumor measurement in Waldenström macroglobulinemia. Blood 2011;116:5076. Go to PubMed...
  19. Manier S, Lejeune J, Musset L, Boyle E, Dulery R, Debarri H, Faucompret JL, Gauthier J, Bories C, Fouquet G, Herbaux Ch, Trict S, Pietrantuono A, Combat F, Poulain S, Harding S, Leblond V, Leleu X. Hevylite, a novel M-component based biomarkers of response to therapy and survival in Waldenström macroglobulinemia. Blood 2011;118:2667.
  20. Ludwig H, Faint J, Milosavljevic D, Zojer N, Bradwell A, Harding S. Ig´κ/Ig´λ measurements improve disease monitoring and identify minimal residual disease in patients with multiple myeloma. Haematologica 2011;96 (S2):368.
  21. Kim J, Hayton WL, Robinson JM, Anderson CL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol 2007; 122:146-55. Go to original source... Go to PubMed...
  22. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cell functions to protect serum IgG from catabolism. J Immunol 2007; 179:4580-8. Go to original source... Go to PubMed...
  23. Anderson CL, Chandhury C, Kim J, Bronson CL, Wani MA, Mohanty S. Perspective FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 2006;27:343-8. Go to original source... Go to PubMed...
  24. Chandhury C, Brooks C, Carter D, Robinson JM, Anderson CL. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry 2006;45:4983-90. Go to original source... Go to PubMed...
  25. Avet-Loiseau H, Harousseau JL, Moreau P, Mathiot C, Facon T, Attal M. Heavy/light chain specific immunoglobulin ratios at presentation are prognostic for progression free survival in the IFM 2005-01 myeloma trial. Blood 2009;114:1818a. Go to PubMed...
  26. Avet-Loiseau H, Mirbahai L, Harousseau JL, Moreau M, Mathiot C, Facon T. Serum immunoglobulin heavy/light chain ratios are independent risk factors for predict progression free survival in multiple myeloma. Haematologica 2010;95:953a. Go to PubMed...
  27. Leleu X, Koulieris E, Maltezas D, Itzykson R, Xie W, Manier S, Dulery R, Boyle E, Gauthier J, Poulain S, Tatiana T, Panayiotidis P, Bradwell AR, Harding S, Leblond V, Kyrtsonis MCH, Ghobrial IM. Novel M-component based biomarkers in Waldenström's macroglobulinemia. Clin Lymphoma, Myeloma § Leukemia 2011;11:164-7.
  28. Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ, Benson JT, Colby CL, Dispenzieri A, Landgren O, Kumar S, Bradwell AR, Cerhan JR, Rajkumar SV. Supression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia 2013;27:208-12. Go to original source... Go to PubMed...
  29. Katzmann JA, Rajkumar SV. A windows into immunoglobulin quantitation and plasma cell disease: antigen epitopes defined by the junction of immunoglobulin heavy and light chains. Leukemia 2013;27:1-2. Go to original source... Go to PubMed...
  30. Ludwig H, Faint J, Zojer N, Bradwel AR, Young P, Milosavljevic D. Serum heavy/light chain and free light chain measurements provide prognostic information, allow creation of a prognostic model and identify clonal changes (clonal tiding) through the course of multiple myeloma (MM). Blood 2011;118:2883a.
  31. Tovar N, Fernandez de Larrea C, Elena M, Cibeira MAT, Arostegui JI, Rosinol L, Filella X, Yagüe J, Blade J. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation. Biol Blood Marrow Transplant 2012;18:1076-7. Go to original source... Go to PubMed...
  32. Wang H, Gao C, Xu L. Laboratory characterisations on 2007 cases of monoclonal gammopathies in East China. Cell Moll Immunol 2008;5:293-8. Go to original source... Go to PubMed...
  33. Alexanian R. Blood volume in monoclonal gammopathy. Blood 1997;49:301-7. Go to PubMed...
  34. Ludwig H, Milosavljevic D, Zojer N, Berlanga O, Hübl W, Harding S. Suppression of the non-involved HLC pair correlates with survival in newly diagnosed and relapsed/refractory patients with myeloma. Congress of European Haematology Association, Milano 2014:P-980.
  35. Finlay JA, Wu AHB. Biological variation of immunoglobulin heavy chain-light Chain pairs in serum. Clin Chim Acta 2014; Available from: http://dx.doi.org/10.1016/j.cca.2014.05.002 Go to original source... Go to PubMed...
  36. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Langren O, Paiva B, Dispenzieri A, Weiss B, Leleu X, Zweengman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM, San Miguel JF. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48. Go to original source... Go to PubMed...